Nathan Jones, MD
Hospice and Palliative Medicine · Newnan, GANPI 1962852632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novo Nordisk at 27.0% of the total. Reporting peaked in 2023 at $209 and has fallen 92.9% since, to $15 in 2025.
Across 43 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$176
- Novartis$84
- Lilly USA, LLC$58
- GSK$48
- Sun Pharmaceutical Industries Inc.$44
- Boehringer Ingelheim$30
- plus $212 from 11 others
What the payments were for
- Food & beverage$63698%
- Education$152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $176 |
| Novartis | 6 | $84 |
| Lilly USA, LLC | 4 | $58 |
| GSK | 3 | $48 |
| Sun Pharmaceutical Industries Inc. | 3 | $44 |
| Boehringer Ingelheim | 2 | $30 |
| AstraZeneca | 2 | $30 |
| Pfizer | 2 | $28 |
| AbbVie | 2 | $26 |
| Sanofi Pasteur Inc. | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$651 in reported general payments places this provider in the 80th percentile of 69 hospice and palliative medicine providers in Georgia.
See all hospice and palliative medicine providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $55,129 |
| EliquisApixaban | 52 | $40,350 |
| JardianceEmpagliflozin | 41 | $38,315 |
| RybelsusSemaglutide | 14 | $28,025 |
| XareltoRivaroxaban | 27 | $23,243 |
| LinzessLinaclotide | 11 | $10,489 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,311 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,781 |
| Dexlansoprazole DrDexlansoprazole | 17 | $3,535 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,485 |
| Levothyroxine Sodium | 178 | $1,867 |
| Tramadol Hcl | 69 | $1,602 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,510 |
| SynthroidLevothyroxine Sodium | 20 | $1,425 |
| Atorvastatin Calcium | 229 | $1,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $176 | $83,15355 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $30 | $46,09656 claims |
| PfizerEliquis | $28 | $40,35052 claims |
| AbbVieLinzess, Synthroid | $26 | $11,91431 claims |
| GSKTrelegy Ellipta | $48 | $10,31114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 69 hospice and palliative medicine providers in Georgia.
Other hospice and palliative medicine in Newnan
- Veronica SudekumWarner Robins$7K
- Anthony EkwenchiAustell$5K
- Joshua JacksonAtlanta$5K
- Nokuthula MsimangaMarietta$3K
- Halima DaboikoKennesaw$3K
- Michelle ParkMarietta$2K
- Olumuyiwa AdeboyeLagrange$2K
- Mary KeithGainesville$2K
- Tanya NikolovaMarietta$1K
- Christina ChenMarietta$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.